Pieter Lindenbergh, Senior Staff Associate at Columbia University Irving Medical Center in the lab of Michel Sadelain and Researcher at Amsterdam UMC, shared on LinkedIn:
“CAR T cell therapy shows clinical efficacy against an increasing number of cancer types but comes with its own unique toxicity profile. In the latest publication from the Sadelain lab, we uncover CAR T cell-derived TNF as a master regulator of cytokine release syndrome, shedding light on the interaction between CAR T cells and macrophages in a mouse model.
Check it out on the Science Immunology website below, and DM me if you encounter access issues. Thanks to Theodore Giavridis, Ph.D. and all co-authors. ”
Title: CAR T cell–derived TNF is an early determinant of cytokine release syndrome severity
Authors: Pieter L. Lindenbergh, Theodoros Giavridis, Ophélie Vivier, Michael A. Lopez, Anton Dobrin, Matthias Mack, José L. Cohen, Maria Themeli, and Michel Sadelain
You can also read: CAR T Cell Therapy Leads to 10-Year Remissions in B-Cell Lymphoma Patients – University of Pennsylvania
